549 related articles for article (PubMed ID: 18497466)
1. Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
Shimamoto K; Fujita T; Ito S; Naritomi H; Ogihara T; Shimada K; Tanaka H; Yoshiike N;
Hypertens Res; 2008 Mar; 31(3):469-78. PubMed ID: 18497466
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
3. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
5. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
7. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Suzuki H; Kanno Y;
Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
[TBL] [Abstract][Full Text] [Related]
8. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Nakamura T; Kanno Y; Takenaka T; Suzuki H;
Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
10. Pulse pressure monitoring of open antihypertensive therapy.
Safar ME; Vaisse B; Blacher J; Rudnichi A; Mourad JJ
Am J Hypertens; 2004 Dec; 17(12 Pt 1):1088-94. PubMed ID: 15607613
[TBL] [Abstract][Full Text] [Related]
11. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension.
Eto M; Toba K; Akishita M; Kozaki K; Watanabe T; Kim S; Hashimoto M; Ako J; Iijima K; Sudoh N; Yoshizumi M; Ouchi Y
Hypertens Res; 2005 Jan; 28(1):1-7. PubMed ID: 15969248
[TBL] [Abstract][Full Text] [Related]
12. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
13. Current status of antihypertensive prescription and associated blood pressure control in Japan.
Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
[TBL] [Abstract][Full Text] [Related]
14. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy.
Hata Y; Muratani H; Kimura Y; Fukiyama K; Kawano Y; Ashida T; Yokouchi M; Imai Y; Ozawa T; Fujii J; Omae T
J Hum Hypertens; 2002 Feb; 16(2):141-6. PubMed ID: 11850772
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
16. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study.
Nielsen WB; Vestbo J; Jensen GB
J Hum Hypertens; 1995 Mar; 9(3):175-80. PubMed ID: 7783098
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
Ellis D; Moritz ML; Vats A; Janosky JE
Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
[TBL] [Abstract][Full Text] [Related]
18. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
Cruickshank JM; Pennert K; Sörman AE; Thorp JM; Zacharias FM; Zacharias FJ
J Hypertens; 1987 Aug; 5(4):489-98. PubMed ID: 3668249
[TBL] [Abstract][Full Text] [Related]
19. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
[TBL] [Abstract][Full Text] [Related]
20. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
